Drug Trial Radar · NCT05303285
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 14, 2024
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wuhan Central Hospital; Wuhan Hospital of Traditional Chinese Medicine; Novartis; Johns Hopkins Bloomberg School of Public Health
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Conditions
- Ankylosing Spondylitis (AS)
Interventions
Secukinumab 300mg s.c.Drug
Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
Secukinumab 150mg s.c.Drug
Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 24Time frame: 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Department of RheumatologyTongji Hospital
Wuhan, Hubei, China · Recruiting
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.